Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

461.70 +10.73 (+2.38%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
54 55 Next >
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals
Via Benzinga
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
Vertex Pharmaceuticals: Buy, Sell, or Hold?
The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run? 
Via The Motley Fool
1 Top Growth Stock to Buy and Hold Forever
This drugmaker looks unstoppable. 
Via The Motley Fool
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock
Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts. 
Via InvestorPlace
Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts
An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack. 
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to... 
Via Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons 
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
The companies expect the deal to close later this quarter. 
Via Investor's Business Daily
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
Vertex to Announce First Quarter 2024 Financial Results on May 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
This innovative machine rolls on. 
Via The Motley Fool
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over 
Via Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term. 
Via InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
These businesses are booming. 
Via The Motley Fool
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
All three companies have very long runways for growth ahead. 
Via The Motley Fool
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations. 
Via The Motley Fool
2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years
Great businesses are here to stay. These are two excellent examples. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
These stocks have exceptionally bright prospects. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.